Screener
Neurocrine Biosciences NBIX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's EBITDA?
- Neurocrine Biosciences (NBIX) reported EBITDA of $200.7M in Q1 2026.
- How has Neurocrine Biosciences's EBITDA changed year-over-year?
- Neurocrine Biosciences's EBITDA increased by 543.3% year-over-year, from $31.2M to $200.7M.
- What is the long-term trend for Neurocrine Biosciences's EBITDA?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's EBITDA has grown at a 34.9% compound annual growth rate (CAGR), from $264.6M to $649.2M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Neurocrine Biosciences's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude